187 related articles for article (PubMed ID: 25339775)
21. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.
Zeuzem S; Buggisch P; Agarwal K; Marcellin P; Sereni D; Klinker H; Moreno C; Zarski JP; Horsmans Y; Mo H; Arterburn S; Knox S; Oldach D; McHutchison JG; Manns MP; Foster GR
Hepatology; 2012 Mar; 55(3):749-58. PubMed ID: 22006408
[TBL] [Abstract][Full Text] [Related]
22. Antiviral Effect of Ribavirin against HCV Associated with Increased Frequency of G-to-A and C-to-U Transitions in Infectious Cell Culture Model.
Galli A; Mens H; Gottwein JM; Gerstoft J; Bukh J
Sci Rep; 2018 Mar; 8(1):4619. PubMed ID: 29545599
[TBL] [Abstract][Full Text] [Related]
23. The role of the equilibrative nucleoside transporter 1 (ENT1) in transport and metabolism of ribavirin by human and wild-type or Ent1-/- mouse erythrocytes.
Endres CJ; Moss AM; Ke B; Govindarajan R; Choi DS; Messing RO; Unadkat JD
J Pharmacol Exp Ther; 2009 Apr; 329(1):387-98. PubMed ID: 19164463
[TBL] [Abstract][Full Text] [Related]
24. Adenosine kinase is a key determinant for the anti-HCV activity of ribavirin.
Mori K; Hiraoka O; Ikeda M; Ariumi Y; Hiramoto A; Wataya Y; Kato N
Hepatology; 2013 Oct; 58(4):1236-44. PubMed ID: 23532970
[TBL] [Abstract][Full Text] [Related]
25. Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients.
Funk EK; Shaffer A; Shivakumar B; Sneller M; Polis MA; Masur H; Heytens L; Nelson A; Kwan R; Kottilil S; Kohli A
AIDS Res Hum Retroviruses; 2013 Sep; 29(9):1190-4. PubMed ID: 23701022
[TBL] [Abstract][Full Text] [Related]
26. Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection.
Pawlotsky JM; Flisiak R; Sarin SK; Rasenack J; Piratvisuth T; Chuang WL; Peng CY; Foster GR; Shah S; Wedemeyer H; Hézode C; Zhang W; Wong KA; Li B; Avila C; Naoumov NV;
Hepatology; 2015 Oct; 62(4):1013-23. PubMed ID: 26118427
[TBL] [Abstract][Full Text] [Related]
27. Inosine Triphosphate Pyrophosphatase Dephosphorylates Ribavirin Triphosphate and Reduced Enzymatic Activity Potentiates Mutagenesis in Hepatitis C Virus.
Nyström K; Wanrooij PH; Waldenström J; Adamek L; Brunet S; Said J; Nilsson S; Wind-Rotolo M; Hellstrand K; Norder H; Tang KW; Lagging M
J Virol; 2018 Oct; 92(19):. PubMed ID: 30045981
[TBL] [Abstract][Full Text] [Related]
28. Characterization of ribavirin uptake systems in human hepatocytes.
Fukuchi Y; Furihata T; Hashizume M; Iikura M; Chiba K
J Hepatol; 2010 Apr; 52(4):486-92. PubMed ID: 20185188
[TBL] [Abstract][Full Text] [Related]
29. Sustained viral response and treatment-induced cytopenia correlate with SLCs and KLF12 genotypes in interferon/ribavirin-treated Chinese chronic hepatitis C patients.
Mei R; Chi X; Wu R; Xu H; Wang X; Gao X; Sun H; Lv J; Yu G; Kong F; Jiang J; Sun B; Zhong J; Pan Y; Niu J
J Gastroenterol Hepatol; 2016 Aug; 31(8):1489-97. PubMed ID: 26750805
[TBL] [Abstract][Full Text] [Related]
30. Silibinin inhibits hepatitis C virus entry into hepatocytes by hindering clathrin-dependent trafficking.
Blaising J; Lévy PL; Gondeau C; Phelip C; Varbanov M; Teissier E; Ruggiero F; Polyak SJ; Oberlies NH; Ivanovic T; Boulant S; Pécheur EI
Cell Microbiol; 2013 Nov; 15(11):1866-82. PubMed ID: 23701235
[TBL] [Abstract][Full Text] [Related]
31. Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy.
Saito Y; Imamura M; Uchida T; Osawa M; Teraoka Y; Fujino H; Nakahara T; Ono A; Murakami E; Kawaoka T; Miki D; Tsuge M; Serikawa M; Aikata H; Abe-Chayama H; Hayes CN; Chayama K
J Med Virol; 2020 Feb; 92(2):210-218. PubMed ID: 31584207
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA let-7g cooperates with interferon/ribavirin to repress hepatitis C virus replication.
Chou WW; Huang CF; Yeh ML; Tsai YS; Hsieh MY; Huang CI; Huang JF; Tsai PC; Hsi E; Juo SH; Tsai WL; Chuang WL; Yu ML; Dai CY
J Mol Med (Berl); 2016 Mar; 94(3):311-20. PubMed ID: 26489607
[TBL] [Abstract][Full Text] [Related]
33. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.
Laguno M; Von Wichmann MA; Van den Eynde E; Navarro J; Cifuentes C; Murillas J; Veloso S; Martínez-Rebollar M; Guardiola JM; Jou A; Gómez-Sirvent JL; Cervantes M; Pineda JA; López-Calvo S; Carrero A; Montes ML; Deig E; Tapiz A; Ruiz-Mesa JD; Cruceta A; de Lazzari E; Mallolas J
Int J Infect Dis; 2016 Dec; 53():46-51. PubMed ID: 27815225
[TBL] [Abstract][Full Text] [Related]
34. Contribution of ribavirin transporter gene polymorphism to treatment response in peginterferon plus ribavirin therapy for HCV genotype 1b patients.
Tsubota A; Shimada N; Yoshizawa K; Furihata T; Agata R; Yumoto Y; Abe H; Ika M; Namiki Y; Chiba K; Fujise K; Tada N; Aizawa Y
Liver Int; 2012 May; 32(5):826-36. PubMed ID: 22212648
[TBL] [Abstract][Full Text] [Related]
35. Quantification of ENT1 and ENT2 Proteins at the Placental Barrier and Contribution of These Transporters to Ribavirin Uptake.
Nishimura T; Sano Y; Takahashi Y; Noguchi S; Uchida Y; Takagi A; Tanaka T; Katakura S; Nakashima E; Tachikawa M; Maruyama T; Terasaki T; Tomi M
J Pharm Sci; 2019 Dec; 108(12):3917-3922. PubMed ID: 31520644
[TBL] [Abstract][Full Text] [Related]
36. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir.
Vispo E; Barreiro P; Pineda JA; Mira JA; Maida I; Martín-Carbonero L; Rodríguez-Nóvoa S; Santos I; López-Cortes LF; Merino D; Rivero A; Soriano V
Antivir Ther; 2008; 13(3):429-37. PubMed ID: 18572756
[TBL] [Abstract][Full Text] [Related]
37. Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection.
Grebely J; Hellard M; Applegate T; Petoumenos K; Yeung B; Feld JJ; Rawlinson W; Lloyd AR; George J; Kaldor JM; Dore GJ; Matthews GV;
AIDS; 2012 Aug; 26(13):1653-61. PubMed ID: 22555168
[TBL] [Abstract][Full Text] [Related]
38. Persistence of HCV in quiescent hepatic cells under conditions of an interferon-induced antiviral response.
Bauhofer O; Ruggieri A; Schmid B; Schirmacher P; Bartenschlager R
Gastroenterology; 2012 Aug; 143(2):429-38.e8. PubMed ID: 22522091
[TBL] [Abstract][Full Text] [Related]
39. Sustained virologic response to standard interferon or pegylated interferon and ribavirin in patients with hepatitis C virus genotype 5: systematic review and meta-analysis of ten studies and 423 patients.
Devaki P; Jencks D; Yee BE; Nguyen MH
Hepatol Int; 2015 Jul; 9(3):431-7. PubMed ID: 26016464
[TBL] [Abstract][Full Text] [Related]
40. Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy.
Kondo Y; Ueno Y; Ninomiya M; Tamai K; Tanaka Y; Inoue J; Kakazu E; Kobayashi K; Kimura O; Miura M; Yamamoto T; Kobayashi T; Igarashi T; Shimosegawa T
J Gastroenterol; 2012 Dec; 47(12):1323-35. PubMed ID: 22588246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
